Terns Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Terns Pharmaceuticals, Inc.

Apr-27	Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia GlobeNewswire
Apr-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Mar-25	Merck to Acquire Terns Pharmaceuticals, Inc., Expanding Its Hematology Pipeline With TERN-701, a Novel Candidate for Chronic Myeloid Leukemia (CML) GlobeNewswire
Feb-25	Terns Pharmaceuticals to Participate in Upcoming March Investor Conferences GlobeNewswire
Feb-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Jan-07	Terns Pharmaceuticals to Highlight 2026 Priorities and Program Milestones at the 44th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Dec-11	Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase Additional Shares GlobeNewswire
Dec-09	Terns Announces Pricing of Upsized $650 Million Public Offering GlobeNewswire
Dec-09	Terns Announces Proposed Public Offering GlobeNewswire
Dec-08	Terns Highlights Additional Positive Phase 1 Clinical Data Supporting TERN-701's Best-in-Disease Potential in Relapsed/Refractory CML at the 67th ASH Annual Meeting GlobeNewswire
Nov-14	Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London GlobeNewswire
Nov-10	Terns Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire
Nov-04	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Nov-03	Terns Announces Abstract with Positive Clinical Data for TERN-701 in Relapsed/Refractory CML Selected for Oral Presentation at 67th ASH Annual Meeting GlobeNewswire
Oct-21	Terns Pharmaceuticals Reports Topline 12-week Data from its Phase 2 Trial Evaluating Oral GLP-1 Receptor Agonist TERN-601 in Obesity GlobeNewswire
Oct-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Aug-21	Terns Pharmaceuticals to Host an Educational Webinar on TERN-701 for Investors in Advance of Phase 1 Data Expected in Fourth Quarter 2025 GlobeNewswire
Aug-05	Terns Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire
Aug-04	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire
Jun-23	Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions GlobeNewswire
May-29	Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences GlobeNewswire
May-14	Terns Pharmaceuticals Selected for Oral Presentation at European Hematology Association Congress For Preclinical Data on Novel Allosteric BCR-ABL Inhibitor TERN-701 GlobeNewswire
May-08	Terns Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Updates GlobeNewswire
May-02	Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4) GlobeNewswire

Terns Pharmaceuticals, Inc.

Recent Articles by Terns Pharmaceuticals, Inc.

Upgrade your Finviz experience